Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study

This study aimed at evaluating the effects of sacubitril/valsartan on neprilysin (NEP), and the metabolism of natriuretic peptides in heart failure (HF) and providing additional mechanistic information on the mode of action of the drug.

[1]  A. Mebazaa,et al.  Plasma neprilysin concentration during recovery from acute illness. , 2018, European heart journal.

[2]  Jagmeet P. Singh,et al.  The heart regulates the endocrine response to heart failure: cardiac contribution to circulating neprilysin , 2018, European heart journal.

[3]  S. Solomon,et al.  Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) , 2018, Circulation. Heart failure.

[4]  J. Lupón,et al.  Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure , 2017, Journal of the American Heart Association.

[5]  N. Vodovar,et al.  Sacubitril/valsartan in PARADIGM-HF. , 2017, The lancet. Diabetes & endocrinology.

[6]  J. Butler,et al.  Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes? , 2017, The lancet. Diabetes & endocrinology.

[7]  Akshay S. Desai,et al.  Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. , 2017, The lancet. Diabetes & endocrinology.

[8]  D. Campbell,et al.  Long-term neprilysin inhibition — implications for ARNIs , 2017, Nature Reviews Cardiology.

[9]  Akshay S. Desai,et al.  Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. , 2016, Journal of the American College of Cardiology.

[10]  A. Bayés‐Genís,et al.  A Test in Context: Neprilysin: Function, Inhibition, and Biomarker. , 2016, Journal of the American College of Cardiology.

[11]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[12]  A. Cohen-Solal,et al.  Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure. , 2015, International journal of cardiology.

[13]  A. Mebazaa,et al.  Unraveling N-terminal pro-B-type natriuretic peptide: another piece to a very complex puzzle in heart failure patients. , 2015, Clinical chemistry.

[14]  A. Cohen-Solal,et al.  Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure. , 2015, JACC. Heart failure.

[15]  M. de Antonio,et al.  Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. , 2015, Journal of the American College of Cardiology.

[16]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.

[17]  A. Mebazaa,et al.  Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. , 2014, European heart journal.

[18]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[19]  J. Burnett,et al.  Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. , 2013, European heart journal.

[20]  A. G. Semenov,et al.  Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. , 2009, Clinical chemistry.

[21]  A. Jaffe,et al.  Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. , 2008, Clinical chemistry.

[22]  A. Richards,et al.  Regional plasma levels of cardiac peptides and their response to acute neutral endopeptidase inhibition in man. , 1998, Clinical science.

[23]  A. Kenny,et al.  Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. , 1993, The Biochemical journal.

[24]  Jagmeet P. Singh,et al.  Soluble CD146 Is a Novel Marker of Systemic Congestion in Heart Failure Patients: An Experimental Mechanistic and Transcardiac Clinical Study. , 2017, Clinical chemistry.